Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): a, double-blind, randomised, controlled phase 3 trial

Raches Ella, Siddarth Reddy, William Blackwelder, Varsha Potdar, Pragya Yadav, Vamshi Sarangi, Vinay Kumar Aileni, Suman Kanungo, Sanjay Rai, Prabhakar Reddy, Savitha Verma, Chandramani Singh, Sagar Redkar, Satyajit Mohapatra, Anil Pandey, Pajanivel Ranganadin, Raghavendra Gumashta, Manish Multani, Shameem Mohammad, Parul Bhatt, Laxmi Kumari, Gajanan Sapkal, Nivedita Gupta, Priya Abraham, Samiran Panda, Sai Prasad, Balram Bhargava, Krishna Ella, Krishna Mohan Vadrevu, the COVAXIN Study Group
doi: https://doi.org/10.1101/2021.06.30.21259439

Article Information

doi 
https://doi.org/10.1101/2021.06.30.21259439
History 
  • July 2, 2021.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Author Information

  1. Raches Ella1,&,
  2. Siddarth Reddy1,
  3. William Blackwelder2,
  4. Varsha Potdar3,
  5. Pragya Yadav3,
  6. Vamshi Sarangi1,
  7. Vinay Kumar Aileni1,
  8. Suman Kanungo4,
  9. Sanjay Rai5,
  10. Prabhakar Reddy6,
  11. Savitha Verma7,
  12. Chandramani Singh8,
  13. Sagar Redkar9,
  14. Satyajit Mohapatra10,
  15. Anil Pandey11,
  16. Pajanivel Ranganadin12,
  17. Raghavendra Gumashta13,
  18. Manish Multani14,
  19. Shameem Mohammad15,
  20. Parul Bhatt16,
  21. Laxmi Kumari17,
  22. Gajanan Sapkal3,
  23. Nivedita Gupta18,
  24. Priya Abraham3,
  25. Samiran Panda18,
  26. Sai Prasad1,
  27. Balram Bhargava17,
  28. Krishna Ella1,
  29. Krishna Mohan Vadrevu1,
  30. the COVAXIN Study Group
  1. 1Bharat Biotech, Hyderabad, India
  2. 2WB Statistical Consulting LLC, Bethesda, Maryland, USA
  3. 3Indian Council of Medical Research-National Institute of Virology, Pune, India
  4. 4Indian Council of Medical Research-National Institute of Cholera and Enteric Diseases, Kolkatta, India
  5. 5All India Institute of Medical Sciences, New Delhi, India
  6. 6Nizams Institute of Medical Sciences, Hyderabad, India
  7. 7Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences, Rohtak, India
  8. 8All India Institute of Medical Sciences, Patna, India
  9. 9Redkar Hospital, Panjim, India
  10. 10SRM Hospital and Research Centre, Chennai, India
  11. 11ESIC Medical College and Hospital, Faridabad, India
  12. 12Mahatma Gandhi Medical College & Research Institute, Pondicherry, India
  13. 13People’s University, Bhopal, India
  14. 14Rahate Surgical Hospital, Nagpur, India
  15. 15Aligarh Muslim University, Aligarh, India
  16. 16GMERS Medical College and Civil Hospital, Ahmedabad, India
  17. 17Government Fever Hospital, Guntur, India
  18. 18Indian Council of Medical Research, New Delhi, India
  1. ↵*Corresponding author; email: rachesella{at}gmail.com
Back to top
Posted July 02, 2021.
Download PDF

Supplementary Material

Data/Code
Email
Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): a, double-blind, randomised, controlled phase 3 trial
Raches Ella, Siddarth Reddy, William Blackwelder, Varsha Potdar, Pragya Yadav, Vamshi Sarangi, Vinay Kumar Aileni, Suman Kanungo, Sanjay Rai, Prabhakar Reddy, Savitha Verma, Chandramani Singh, Sagar Redkar, Satyajit Mohapatra, Anil Pandey, Pajanivel Ranganadin, Raghavendra Gumashta, Manish Multani, Shameem Mohammad, Parul Bhatt, Laxmi Kumari, Gajanan Sapkal, Nivedita Gupta, Priya Abraham, Samiran Panda, Sai Prasad, Balram Bhargava, Krishna Ella, Krishna Mohan Vadrevu, the COVAXIN Study Group
medRxiv 2021.06.30.21259439; doi: https://doi.org/10.1101/2021.06.30.21259439
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area